8-chloro-cAMP inhibits smooth muscle cell proliferation in vitro and neointima formation induced by balloon injury in vivo

J Am Coll Cardiol. 2000 Jul;36(1):288-93. doi: 10.1016/s0735-1097(00)00679-3.

Abstract

Objectives: The aims of the present study were to assess 1) the effect of 8-C1-cAMP (cyclic-3'-5'-adenosine monophosphate) on vascular smooth muscle cell (VSMC) proliferation in vitro and 2) the efficacy of systemic administration of 8-C1-cAMP on neointimal formation after balloon injury in vivo.

Background: Neointimal formation after vascular injury is responsible for restenosis after arterial stenting. Recently, 8-C1-cAMP, a cAMP analogue that induces growth arrest, has been safely administered in phase I studies in humans.

Methods: The effect of 8-C1-cAMP on cell proliferation was first assessed on SMCs in vitro. To study the effects of cAMP in vivo, balloon injury was performed in 67 rats using a 2F Fogarty balloon catheter.

Results: The 8-C1-cAMP markedly inhibited VSMC proliferation in vitro, reduced protein kinase A (PKA) RIalpha subunit expression, and induced PKA RIIbeta subunit expression. In addition, 8-C1-cAMP reduced, in a dose-dependent manner, neointimal area and neointima/media ratio after balloon injury. The proliferative activity, assessed by proliferating nuclear cell antigen immunostaining, revealed a reduction of proliferative activity of VSMCs in vivo in the 8-C1-cAMP group. Moreover, the systemic administration of 8-C1-cAMP did not affect renal function, blood pressure and heart rate.

Conclusions: We conclude that 8-C1-cAMP potently inhibits VSMC proliferation in vitro and reduces neointima formation by balloon injury in vivo after systemic administration. These data may have a clinical relevance in designing future strategies to prevent restenosis after arterial stenting and perhaps after percutaneous transluminal coronary angioplasty.

Publication types

  • Comparative Study

MeSH terms

  • 8-Bromo Cyclic Adenosine Monophosphate / administration & dosage
  • 8-Bromo Cyclic Adenosine Monophosphate / analogs & derivatives*
  • 8-Bromo Cyclic Adenosine Monophosphate / pharmacology
  • Animals
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / pharmacology*
  • Aorta, Thoracic / injuries
  • Aorta, Thoracic / pathology
  • Arterial Occlusive Diseases / enzymology
  • Arterial Occlusive Diseases / metabolism
  • Arterial Occlusive Diseases / prevention & control
  • Blood Pressure / drug effects
  • Catheterization / adverse effects
  • Cell Division / drug effects
  • Cells, Cultured
  • Cyclic AMP-Dependent Protein Kinase RIIbeta Subunit
  • Cyclic AMP-Dependent Protein Kinase RIalpha Subunit
  • Cyclic AMP-Dependent Protein Kinases / metabolism
  • Down-Regulation / drug effects
  • Heart Rate / drug effects
  • Injections, Intraperitoneal
  • Muscle, Smooth, Vascular / cytology
  • Muscle, Smooth, Vascular / drug effects*
  • Muscle, Smooth, Vascular / enzymology
  • Rats
  • Rats, Wistar
  • Tunica Intima / cytology
  • Tunica Intima / drug effects*
  • Tunica Intima / enzymology
  • Up-Regulation / drug effects

Substances

  • Antineoplastic Agents
  • Cyclic AMP-Dependent Protein Kinase RIIbeta Subunit
  • Cyclic AMP-Dependent Protein Kinase RIalpha Subunit
  • Prkar1a protein, rat
  • Prkar2b protein, rat
  • 8-Bromo Cyclic Adenosine Monophosphate
  • 8-chloro-cyclic adenosine monophosphate
  • Cyclic AMP-Dependent Protein Kinases